Clearside Biomedical (CLSD) Scheduled to Post Earnings on Wednesday

Clearside Biomedical (NASDAQ:CLSD) is set to release its earnings data after the market closes on Wednesday, August 7th. Analysts expect Clearside Biomedical to post earnings of ($0.37) per share for the quarter.

Clearside Biomedical (NASDAQ:CLSD) last issued its quarterly earnings data on Wednesday, May 8th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.09). The business had revenue of $0.05 million for the quarter. On average, analysts expect Clearside Biomedical to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Shares of Clearside Biomedical stock traded down $0.02 during trading hours on Monday, reaching $1.05. The stock had a trading volume of 75,417 shares, compared to its average volume of 253,374. The company’s 50 day simple moving average is $1.09. The stock has a market cap of $39.86 million, a price-to-earnings ratio of -0.39 and a beta of -0.88. Clearside Biomedical has a twelve month low of $0.95 and a twelve month high of $8.25. The company has a quick ratio of 3.04, a current ratio of 3.04 and a debt-to-equity ratio of 0.61.

A number of brokerages have weighed in on CLSD. Wedbush reiterated an “outperform” rating and issued a $4.00 price objective on shares of Clearside Biomedical in a research report on Monday, July 29th. ValuEngine upgraded shares of Clearside Biomedical from a “sell” rating to a “hold” rating in a research report on Thursday. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the stock. Clearside Biomedical presently has an average rating of “Hold” and an average price target of $3.71.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc, a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion.

Featured Story: Momentum Indicators

Earnings History for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with's FREE daily email newsletter.